Table 3. Summary of the adverse events (AEs) by treatment allocation.

Variable		Placebo	PGX	P-value
Number of participants		38	42
Participants reporting adverse events		13 (34.2%)	12 (28.6%)	0.7
Total adverse events		25	28
Participants reporting treatment-related events		8 (21.1%)	11 (26.2%)	0.34
Total treatment-related Events		19	24
Total adverse events (by severity)	Unknown severity	0	0
	Mild	5	2
	Moderate	13	21
	Severe	7	5
Total treatment-related events (by severity)	Unknown Severity	0	0
	Mild	4	2
	Moderate	9	18
	Severe	6	4
Participants reporting AEs by type of AE	Constipation	3 (7.9%)	1 (2.4%)	0.15
	Diarrhea	0 (0.0%)	3 (7.1%)	NA
	Bloating	4 (10.5%)	8 (19%)	0.07
	Flatulence	0 (0.0%)	2 (4.8%)	NA
	Headache	4 (10.5%)	1 (2.4%)	0.17
	Cramping	3 (7.9%)	3 (7.1%)	0.59
	Sick/unwell	4 (10.5%)	1 (2.4%)	0.08
	Other	3 (7.9%)	7 (16.7%)	0.06

Abbreviation: PGX, PolyGlycopleX.

Parentheses denote the percentage from the total number of participants.

Some P-values were not possible to compute due to no events being reported under one of the treatment groups. These are noted as ‘NA' in the table.